ICARUS-LUNG01-ExomeSeq

Whole exome sequencing (WES) on frozen tumor biopsies at BL to identify genomic alterations associated with response/resistance. Non- synonymous point mutations, indels, homozygous deletions, loss of heterozygosity (LOH) and low, medium, and high-level amplifications were assessed.

Type: Exome Sequencing
Archiver: European Genome-Phenome Archive (EGA)

1 Dataset

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD50000001014	A total of 46 frozen tumor biopsies underwent WES analysis, while 41 blood samples were used as germline controls.Tumor samples qualified for whole exome sequencing (WES) if they contained ≥10% tumor cells. For bulk RNA-seq, 20 paired baseline and on-treatment frozen tumor biopsies were analyzed. Tumor samples qualified if they contained ≥30% tumor cells.	Illumina NovaSeq 6000	127